Atrium Therapeutics, Inc. (RNA) NASDAQ
13.30
+0.16(+1.22%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.30
+0.16(+1.22%)
Currency In USD
Address
10578 Science Center Drive
San Diego, CA 92121
United States of America (the)
Phone
619 876 0700
Sector
Healthcare
Industry
Biotechnology
Employees
511
First IPO Date
February 27, 2026
| Name | Title | Pay | Year Born |
| Kathleen Gallagher | President, CEO & Director | 0 | 1982 |
| Brendan Winslow | Chief Financial Officer | 0 | 1988 |
| Stephanie Kenney | Chief Corporate Affairs Officer | 0 | 1978 |
| Husam Younis | Chief Scientific Officer | 0 | 1974 |
| Steven George Hughes | Chief Medical Officer | 0 | 1968 |
| Rocio Martin Hoyos | Chief Strategy Officer | 0 | 1983 |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.